close

Agreements

Date: 2018-11-14

Type of information: Nomination

Compound: vice president

Company: Nektar Therapeutics (USA - CA)

Therapeutic area: Cancer - Oncology

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On November 14, 2018, Nektar Therapeutics announced the appointment of Wei Lin, as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin will lead development strategy and study oversight of the company's immuno-oncology candidates and other oncology programs.
  • From 2011 to 2018, Dr. Lin was at Genentech, where he served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer, developing strategy, executing proof-of-concept and registration trials, and gaining approvals of immunotherapy drugs. During his time at Genentech, he also served as a core member of the Lung and Head and Neck Cancer Franchise, identifying opportunities to develop the pipeline and contributing to decisions in funding and acquisitions/partnering opportunities.
  • Prior to joining Genentech, Dr. Lin served as a faculty member at the M.D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and Neck Medical Oncology. He received a B.A. from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center.

Financial terms:

Latest news:

Is general: Yes